Activation of GLP-1R by liraglutide decreases apoptosis in chondrocytes To assess the role of GLP-1R in chondrocytes, we used liraglutide, a GLP-1R agonist, to activate GLP-1R with various concentrations
Storage Instructions: Store lyophilized vials at 28C, protected from light, in the original packaging
6 However, there is still a residual cardiorenal risk that persists when using SGLT2 and ns-MRAs such as kidney function decline, cardiovascular events, and ongoing albuminuria
While many studies have described the advantages of cells derived from these organs, their advantage as a source of younger cells has not been sufficiently covered by the literature
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Efpeglenatide Efpeglenatide is a novel, long-acting GLP-1 receptor agonist developed by Hanmi Pharmaceuticals (South Korea) utilizing the proprietary LAPSCOVERY (Long-Acting Protein/Peptide Discovery) technology platform